Pacific Biosciences of California is a medical devices business based in the US. Pacific Biosciences of California shares (PACB) are listed on the NASDAQ and all prices are listed in US Dollars. Pacific Biosciences of California employs 769 staff and has a trailing 12-month revenue of around $146.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $8.46 |
|---|---|
| 52-week range | $4.97 - $14.55 |
| 50-day moving average | $11.36 |
| 200-day moving average | $11.04 |
| Wall St. target price | $15.58 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.28 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.46 from 2023-09-25
| 1 week (2023-09-20) | -10.29% |
|---|---|
| 1 month (2023-08-25) | -14.72% |
| 3 months (2023-06-27) | -31.83% |
| 6 months (2023-03-24) | -11.97% |
| 1 year (2022-09-23) | N/A |
|---|---|
| 2 years (2021-09-27) | -67.60% |
| 3 years (2020-09-25) | 9.25 |
| 5 years (2018-09-27) | 52.43% |
| Revenue TTM | $146.1 million |
|---|---|
| Gross profit TTM | $53.5 million |
| Return on assets TTM | -10.05% |
| Return on equity TTM | -48.22% |
| Profit margin | -218.43% |
| Book value | $2.56 |
| Market Capitalization | $2.1 billion |
TTM: trailing 12 months
We're not expecting Pacific Biosciences of California to pay a dividend over the next 12 months.
Over the last 12 months, Pacific Biosciences of California's shares have ranged in value from as little as $4.97 up to $14.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacific Biosciences of California's is 1.6411. This would suggest that Pacific Biosciences of California's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.